FDA Asked to Approve Darzalex Triple Combo for Relapsed or Refractory Multiple Myeloma
Janssen has asked the U.S. Food and Drug Administration (FDA) to allow Darzalex…
Ana Pena, PhD, — 
Articles by Ana Pena
Bone Marrow Macrophages Could Predict Resistance to Velcade, Study Suggests
The multiple myeloma therapy Velcade (bortezomib) can induce the formation of pro-inflammatory macrophages — a kind of white blood cell —…
Tally of Risk Factors Can Identify Myeloma Patients at Risk of Deep-vein Blood Clots, Study Suggests
A simple score of risk factors could help alert doctors to a likelihood of dangerous blood clots, called venous thromboembolism, forming as a side…
CAR T-Cell Candidate bb2121 Shows Promise in Heavily Pre-treated Myeloma, Interim Data Show
The candidate CAR-T cell therapy bb2121 showed a favorable safety profile and eliminated traces…
Pivotal OPTIMISMM Trial Shows Benefits of Pomalyst Triple Combo Therapy
Treatment with Pomalyst (pomalidomide) in combination with Velcade (bortezomib) and dexamethasone prolongs survival without disease worsening…
Revlimid and Imnovid Triple Combos Approved in EU for Adults with Multiple Myeloma
The European Commission has approved two combination therapies based on Celgene‘s Revlimid (lenalidomide) and Imnovid (pomalidomide), added to Velcade (…
Investigational Ygalo Shows Promise for Relapsed or Refractory Multiple Myeloma, Interim Data Show
Ygalo (melflufen), a novel compound under investigation for relapsed and refractory multiple myeloma, was well-tolerated and…
Kyprolis Combo Yields Positive Results as Initial Treatment for Multiple Myeloma
A combination of Kyprolis (carfilzomib) and dexamethasone, already approved for relapsed and refractory multiple myeloma,…
FDA Grants Poseida’s P-BCMA-101 RMAT Status for Treatment of Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has granted P-BCMA-101, Poseida Therapeutics’…
New Compound Safely Halts Advanced Myeloma Progression in Small Pilot Study
A new investigational compound targeting a central pathway in cancer development showed promising results in patients with relapsed or refractory multiple myeloma…